LIPOSOMES |
✓ Entrapment of hydrophilic and hydrophobic compounds separated or simultaneously. |
✗ Reduction in encapsulation efficiency due to size enlargement |
✓ The increase in number of layers (e.g., kinetic constraints) may be beneficial to prevents or delays the release of active molecules. |
✗ Higher physical instability during storage. |
✓ Made of natural ingredients |
✗ Susceptibility to fast clearance from the bloodstream |
✓ Simple fabrication process |
✗ Drug leakage |
✓ Possibility of surface functionalization |
✗ Higher susceptibility to be capture by RES |
✓ Cost-effectiveness |
✗ Reduced bioavailability compared to nanoliposomes |
NANOLIPOSOMES |
✓ Entrapment of hydrophilic and hydrophobic compounds separated or simultaneously. |
✗ Manufacturing process usually involves mechanical energy (e.g., sonication, homogenization, microfluidization, etc.) that may degrade the lipid structure. |
✓ Reduced toxicity and side-effects |
✗ Aggregation and coalescence can occur due to stronger electrostatic interactions. |
✓ Greater stability when incorporated into real products |
✗ More clinical trials are still necessary |
✓ Higher surface area-to-volume ratio |
✗ In some cases, the use of surfactants as stabilizers is needed. |
✓ Better solubility and accurate targeting |
✗ Reduced drug storage capacities |
✓ Delayed body clearance and better suitability for chemotherapeutics delivery |
✗ The in vivo fate is still not fully understood |